» Articles » PMID: 36504404

Experimental Heart Failure Models in Small Animals

Overview
Journal Heart Fail Rev
Date 2022 Dec 12
PMID 36504404
Authors
Affiliations
Soon will be listed here.
Abstract

Heart failure (HF) is one of the most critical health and economic burdens worldwide, and its prevalence is continuously increasing. HF is a disease that occurs due to a pathological change arising from the function or structure of the heart tissue and usually progresses. Numerous experimental HF models have been created to elucidate the pathophysiological mechanisms that cause HF. An understanding of the pathophysiology of HF is essential for the development of novel efficient therapies. During the past few decades, animal models have provided new insights into the complex pathogenesis of HF. Success in the pathophysiology and treatment of HF has been achieved by using animal models of HF. The development of new in vivo models is critical for evaluating treatments such as gene therapy, mechanical devices, and new surgical approaches. However, each animal model has advantages and limitations, and none of these models is suitable for studying all aspects of HF. Therefore, the researchers have to choose an appropriate experimental model that will fully reflect HF. Despite some limitations, these animal models provided a significant advance in the etiology and pathogenesis of HF. Also, experimental HF models have led to the development of new treatments. In this review, we discussed widely used experimental HF models that continue to provide critical information for HF patients and facilitate the development of new treatment strategies.

Citing Articles

Targeting cardiac fibrosis with Chimeric Antigen Receptor-Engineered Cells.

Zhang Q, Dai J, Liu T, Rao W, Li D, Gu Z Mol Cell Biochem. 2024; .

PMID: 39460827 DOI: 10.1007/s11010-024-05134-6.


SGLT2 inhibition, plasma proteins, and heart failure: a proteome-wide Mendelian Randomization and colocalization study.

Luo J, Shi L, Liu J, Li G, Tu L, Hu S Front Cardiovasc Med. 2024; 11:1371513.

PMID: 38725835 PMC: 11079590. DOI: 10.3389/fcvm.2024.1371513.


Characterization of atrial and ventricular remodeling in an improved minimally invasive mouse model of transverse aortic constriction.

Navarro-Garcia J, Lahiri S, Aguilar-Sanchez Y, Reddy A, Wehrens X J Cardiovasc Aging. 2023; 3(3).

PMID: 37538440 PMC: 10399641. DOI: 10.20517/jca.2023.18.

References
1.
Kittana N . Angiotensin-converting enzyme 2-Angiotensin 1-7/1-9 system: novel promising targets for heart failure treatment. Fundam Clin Pharmacol. 2017; 32(1):14-25. DOI: 10.1111/fcp.12318. View

2.
Raghunathan S, Patel B . Therapeutic implications of small interfering RNA in cardiovascular diseases. Fundam Clin Pharmacol. 2012; 27(1):1-20. DOI: 10.1111/j.1472-8206.2012.01051.x. View

3.
Lubrano V, Balzan S . Role of oxidative stress-related biomarkers in heart failure: galectin 3, α1-antitrypsin and LOX-1: new therapeutic perspective?. Mol Cell Biochem. 2019; 464(1-2):143-152. DOI: 10.1007/s11010-019-03656-y. View

4.
Pagliaro B, Cannata F, Stefanini G, Bolognese L . Myocardial ischemia and coronary disease in heart failure. Heart Fail Rev. 2019; 25(1):53-65. DOI: 10.1007/s10741-019-09831-z. View

5.
Savarese G, Lund L . Global Public Health Burden of Heart Failure. Card Fail Rev. 2017; 3(1):7-11. PMC: 5494150. DOI: 10.15420/cfr.2016:25:2. View